A Study of PM8002 Injection in Combination With Chemotherapy in Patients With NEN
Status:
Recruiting
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the
efficacy and safety of PM8002 in combination with FOLFIRI as second line treatment for
neuroendocrine neoplasm (NEC and Ki-67≥55% G3 NET).